Trial Profile
A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record